Sequential use of bevacizumab and cetuximab in patients with K-RAS wild type advanced colorectal cancer.
2015
e14681 Background: Monoclonal antibodies targeting either VEGF or EGFR have improved the treatment outcomes in patients with advanced colorectal cancer (CRC). Although cetuximab or panitumumab are ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI